Skip to Content

Auranofin Disease Interactions

There are 9 disease interactions with auranofin:

Major

Auranofin (applies to auranofin) bone marrow aplasia

Major Potential Hazard, High plausibility. Applicable conditions: Bone Marrow Depression/Low Blood Counts

The use of auranofin and other gold compounds is contraindicated in patients with a history of gold- induced bone marrow aplasia. Prior to gold compounds therapy, a complete blood count with a differential, platelet count, urinalysis, and renal and liver function tests should be performed. A complete blood count with a differential, platelet count, and urinalysis should be done at least monthly during therapy. Hematological warning signs of gold toxicity include a drop in hemoglobin, leukopenia (WBC < 4,000/mm3), granulocytopenia (< 1,500/mm3), and thrombocytopenia (<100,000/mm3).

References

  1. "Product Information. Ridaura (auranofin)." SmithKline Beecham, Philadelphia, PA.
  2. "Product Information. Myochrysine (gold sodium thiomaleate)." Merck & Co, Inc, West Point, PA.
  3. "Product Information. Solganal (aurothioglucose)." Schering Laboratories, Kenilworth, NJ.
Major

Auranofin (applies to auranofin) gold induced disorders

Major Potential Hazard, Moderate plausibility. Applicable conditions: Inflammatory Bowel Disease, Dermatitis - Drug-Induced, Infectious Diarrhea/Enterocolitis/Gastroenteritis, Idiopathic Pulmonary Fibrosis

The use of auranofin is contraindicated in patients with a history of any of the following gold- induced disorders: anaphylactic reactions, necrotizing enterocolitis, pulmonary fibrosis, and exfoliative dermatitis.

References

  1. "Product Information. Solganal (aurothioglucose)." Schering Laboratories, Kenilworth, NJ.
  2. "Product Information. Myochrysine (gold sodium thiomaleate)." Merck & Co, Inc, West Point, PA.
  3. "Product Information. Ridaura (auranofin)." SmithKline Beecham, Philadelphia, PA.
Major

Gold compounds (applies to auranofin) congestive heart failure

Major Potential Hazard, Moderate plausibility.

The use of gold compounds is contraindicated in patients with uncontrolled congestive heart failure. Prior to initiation of gold compounds medical problems that might affect the signs and symptoms used to detect gold compounds toxicity should be under control.

References

  1. "Product Information. Ridaura (auranofin)." SmithKline Beecham, Philadelphia, PA.
  2. "Product Information. Solganal (aurothioglucose)." Schering Laboratories, Kenilworth, NJ.
  3. "Product Information. Myochrysine (gold sodium thiomaleate)." Merck & Co, Inc, West Point, PA.
Major

Gold compounds (applies to auranofin) diabetes mellitus

Major Potential Hazard, Low plausibility.

The use of gold compounds is contraindicated in patients with controlled diabetes mellitus.

References

  1. "Product Information. Myochrysine (gold sodium thiomaleate)." Merck & Co, Inc, West Point, PA.
  2. "Product Information. Ridaura (auranofin)." SmithKline Beecham, Philadelphia, PA.
  3. "Product Information. Solganal (aurothioglucose)." Schering Laboratories, Kenilworth, NJ.
Major

Gold compounds (applies to auranofin) liver disease

Major Potential Hazard, High plausibility.

The use of gold compounds is contraindicated in patients with hepatic dysfunction. Prior to gold compounds therapy, a complete blood count with a differential, platelet count, urinalysis, and renal and liver function tests should be performed. A complete blood count with a differential, platelet count, and urinalysis should be done at least monthly during therapy.

References

  1. "Product Information. Myochrysine (gold sodium thiomaleate)." Merck & Co, Inc, West Point, PA.
  2. "Product Information. Solganal (aurothioglucose)." Schering Laboratories, Kenilworth, NJ.
  3. "Product Information. Ridaura (auranofin)." SmithKline Beecham, Philadelphia, PA.
Major

Gold compounds (applies to auranofin) rash

Major Potential Hazard, High plausibility. Applicable conditions: Eczema

The use of gold compounds is contraindicated in patients with urticaria or eczema. Prior to initiation of gold therapy, medical problems that might affect the signs and symptoms used to detect gold toxicity should be under control.

References

  1. "Product Information. Solganal (aurothioglucose)." Schering Laboratories, Kenilworth, NJ.
  2. "Product Information. Myochrysine (gold sodium thiomaleate)." Merck & Co, Inc, West Point, PA.
  3. "Product Information. Ridaura (auranofin)." SmithKline Beecham, Philadelphia, PA.
Major

Gold compounds (applies to auranofin) renal dysfunction

Major Potential Hazard, High plausibility.

The use of gold compounds is contraindicated in patients with chronic renal failure. These patients may be at increased risk for renal toxicity. Prior to gold compounds therapy, a complete blood count with a differential, platelet count, urinalysis, and renal and liver function tests should be performed. A complete blood count with a differential, platelet count, and urinalysis should be done at least monthly during therapy.

References

  1. "Product Information. Myochrysine (gold sodium thiomaleate)." Merck & Co, Inc, West Point, PA.
  2. "Product Information. Ridaura (auranofin)." SmithKline Beecham, Philadelphia, PA.
  3. "Product Information. Solganal (aurothioglucose)." Schering Laboratories, Kenilworth, NJ.
Major

Gold compounds (applies to auranofin) severe hypertension

Major Potential Hazard, Moderate plausibility.

The use of gold compounds is contraindicated in patients with severe hypertension. Prior to initiation of gold compounds medical problems that might affect the signs and symptoms used to detect gold compounds toxicity should be under control.

References

  1. "Product Information. Solganal (aurothioglucose)." Schering Laboratories, Kenilworth, NJ.
  2. "Product Information. Myochrysine (gold sodium thiomaleate)." Merck & Co, Inc, West Point, PA.
  3. "Product Information. Ridaura (auranofin)." SmithKline Beecham, Philadelphia, PA.
Major

Gold compounds (applies to auranofin) systemic lupus erythematosus

Major Potential Hazard, High plausibility.

The use of gold compounds is contraindicated in patients with systemic lupus erythematosus. Prior to gold compounds therapy, a complete blood count with a differential, platelet count, urinalysis, and renal and liver function tests should be performed. A complete blood count with a differential, platelet count, and urinalysis should be done at least monthly during therapy.

References

  1. "Product Information. Solganal (aurothioglucose)." Schering Laboratories, Kenilworth, NJ.
  2. "Product Information. Myochrysine (gold sodium thiomaleate)." Merck & Co, Inc, West Point, PA.
  3. "Product Information. Ridaura (auranofin)." SmithKline Beecham, Philadelphia, PA.

Auranofin drug interactions

There are 101 drug interactions with auranofin

Auranofin alcohol/food interactions

There is 1 alcohol/food interaction with auranofin

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.